Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-TB: Imatinib for Tuberculosis
NCT03891901Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in Tuberculosis (TB) (9 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Myelomonocytic Cells in the Blood, Frequency of Grade 3 or 4 Adverse Events at Day 50 and 1 more. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03891901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891901.